A "hit-it-hard, hit-it-early" strategy might eventually cure plaque psoriasis, says the researcher conducting a small study of high-dose Skyrizi that has produced promising results. Even so, the disease is not vanquished and "trickles back."
In an interview, Andrew Blauvelt, MD, MBA, provides further perspective on the approval of roflumilast topical foam, 0.3% (Zoryve) and full publication of phase 3 STRATUM data.